Last updated: 2026-09-16 12:10:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Relmada Therapeutics, Inc. (RLMD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.56, with a market capitalisation of $473.61M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.45 to $8.00. This page covers its latest market performance, valuation, price trends and company information.
$473.61M | |
$4.56 | |
$54.00 | |
$0.24 | |
$4.44 | |
45.00 | |
1.75M | |
-- | |
$8.00 | |
$1.45 | |
-- | |
-- |
Relmada Therapeutics, Inc. (RLMD) is trading at $4.56 in pre-market trading as of 2026-09-16 11:01:00, up 2.59% ($0.11) from the previous close of $4.44
Pre-market trading shows how investors are pricing RLMD before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Relmada Therapeutics, Inc. (RLMD) moved from $4.43 to $4.56, representing a gain of 2.82% ($0.13).
The stock traded between $4.00 and $4.65 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1.81 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 47.4%
RLMD is currently trading at $4.56, placing it 47.4% of the way from its 52-week low of $1.45 to its 52-week high of $8.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Relmada Therapeutics, Inc. (RLMD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.